Nacuity Pharmaceuticals

Dr. Emmett Cunningham, Jr. [Photo: LinkedIn]

Opthalmic Industry Veteran Joins Nacuity Pharmaceuticals’ Board

by | Apr 19, 2024
Emmett T. Cunningham is a senior partner at HealthQuest Capital Management and co-founder and executive chairman of Eyconis, a spinout of Ascendis Pharma.
MORE►
Follow the Money: Video Game Studio Raises $46M for Web3 Play, Medical Device Maker Goes Public, Real Estate Investor Raises $1.8B, and More
by | Jun 17, 2022

What companies are finding funding or having a big exit? From startup investments to grants and acquisitions, Dallas Innovates tracks what’s happening in North Texas money....

MORE►
With $16.5M in New Funding, Fort Worth’s Nacuity Aims to Treat ‘Serious Blinding and Chronic Diseases’
by | Jun 15, 2022
Nacuity Pharmaceuticals focuses on ocular diseases caused by oxidative stress in the retina, including age-related macular degeneration, glaucoma, and diabetic retinopathy. The $16.5M funding, led by the Foundation Fighting Blindness, will help advance two Nacuity clinical trials. “This funding will help further our mission to develop a breakthrough treatment for retinitis pigmentosa and other serious blinding and chronic diseases," said Nacuity Chairman, CEO, and Co-founder Halden Conner.
MORE►
A Special Thank you to our sponsors

A collaboration of the Dallas Regional Chamber and Dallas Next, Dallas Innovates is an online news platform covering what's new + next in Dallas - Fort Worth innovation.

© Copyright 2024 | All rights reserved.

Business

Creative

Education

Impact

Invention

Startup

Our Sponsors

Our Partners